|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Lack of Efficacy of Bevacizumab Plus Irinotecan in Children with Recurrent Malignant Glioma and Diffuse Brainstem Glioma:A Pediatric Brain Tumor Consortium Study显示文摘PURPOSE:A phase Ⅱ study of bevacizumab(BVZ) plus irinotecan(CPT-11) was conducted in children with recurrent malignant glioma(MG) and intrinsic brainstem glioma(BSG).PATIENTS AND METHODS:Eligible patients received two doses of BVZ | Gururangan S Chi SN Young Poussaint T Onar-Thomas A Gilbertson RJ Vajapeyam S Friedman HS Packer RJ Rood BN Boyett JM Kun LE | 2010 | 中国神经肿瘤杂志2010，8，2： | 7 |
| 2 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 3 | Evaluation of meta-astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model显示文摘 | Vaidyanathan G Friedman HS Keir ST | 1996 | Nucl Med Biol1996，23，： | 1 |
| 4 | Resent advances in the treat- ment of malignant astrocytoma 显示文摘 | Reardnn DA Rich JN Friedman HS | 2006 | J Clin Oncol2006，24，8： | 1 |
| 5 | Successful desensitization to earboplatin in patients with systemic hypersensitivity reactions 显示文摘 | Broome CB Schiff RI Friedman HS | 1996 | Med Pediatr Oncol1996，26，2： | 1 |
| 6 | Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft显示文摘 | FRIEDMAN HS JOHNSON SP DONG Q | 1997 | Cancer Res1997，57，14： | 1 |
| 7 | Successful desen- sitization to carboplatin in patients with systemic hypersensitivity reactions 显示文摘 | BROOME CB SCHIFF RI FRIEDMAN HS | 1996 | Med Pediatr O ncol1996，26，2： | 1 |
| 8 | Stress and intervention preferences of patients with brain tumors显示文摘 | Keir ST Guill AB Friedman HS | 2006 | Support Care Canc- er2006，14，12： | 1 |
| 9 | Bevacizumabalone and in combination with irinotecan in recurrent glioblastoma 显示文摘 | Friedman HS Prados MD Wen PY | 2009 | J Clin Oncol2009，27，28： | 1 |
| 10 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastorrta显示文摘 | Friedman HS Prados MD Wen PY et ai | 2009 | Journal of Clincal Oncology2009，27，28： | 1 |
| 11 | Bevaeizumab alone and in combination with irinotecan in recurrent glioblastoma 显示文摘 | Friedman HS Prados MD Wen PY | 2009 | J Clin Oncol2009，27，28： | 1 |
| 12 | Recent advances in the treatment of malignant astrocytoma显示文摘 | Reardon DA Rich JN Friedman HS | 2006 | J Clin Oncol2006，24，8： | 1 |
| 13 | Serum homocysteine and stroke in atrial fibrillation显示文摘 | Friedman HS | 2001 | Ann Intern Med2001，134，25： | 1 |
| 14 | Health Status and the Five-factorPersonality Traits in a Nationally Representative Sample 显示文摘 | Goodwin RD Friedman HS | 2006 | J Health Psychol2006，11，5： | 1 |
| 15 | Resent adwmces in the trealmenl of malignant astroeytoma 显示文摘 | Reardon DA Rich JN Friedman HS | 2006 | J Clin Oncol2006，24，8： | 1 |
| 16 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma显示文摘 | Friedman HS Prados MD Wen PY | 2009 | J Clin Oncol2009，27，28： | 1 |
| 17 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma显示文摘 | Friedman HS Prados MD Wen PY | 2009 | J Clin On- col2009，27，28： | 1 |
| 18 | Irinotecan therapy in adults with recurrent or progressive malignant glioma显示文摘 | Friedman HS Petros WP Friedman AH | | 0，，： | 1 |
| 19 | DNA mismatch repair and O6-alkylguanine DNA alkyhransferase analysis and response to Temodal in newly diagnosed malignant glioma 显示文摘 | Friedman HS McLendon RE Kerby T | 1998 | J Clin Onco11998，16，12： | 1 |
| 20 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma显示文摘 | Friedman HS Prados MD Wen PY | | 0，，28： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员